News

Rinvoq is filed in Japan to treat non-radiographic axial spondyloarthritis .- AbbVie

Read time: 1 mins

Published:17th Mar 2022

Abbvie has filed its JAK inhibitor Rinvoq (upadacitinib) in Japan for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients who have responded inadequately to existing treatments.

This submission is supported by data from a multinational Phase III clinical study, including Japan evaluating the drug in adult patients with active nr-axSpA with objective signs of inflammation who had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs), or intolerance to or contraindication for NSAIDs.

Rinvoq is already approved in Japan for the treatment of rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.

Condition: Axial Spondyloarthritis

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Alecensa (alectinib) as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours greater than 4 cm or node positive), as detected by an FDA-approved test

2 mins

Drug news

Iomab-B (apamistamab) to overcome high-risk TP53 mutation resulting in significant improvement in overall survival in patients with active relapsed refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. announced that results from the Phase III SIERRA trial of Iomab-B (apamistamab) were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17

1 min

Drug news

FDA has granted a rolling New Drug Application (NDA) submission for suzetrigine (VX 548) in moderate-to-severe acute pain

Vertex Pharmaceuticals Incorporated announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548)

1 min

See all news